Veracyte (VCYT) Net Income towards Common Stockholders (2012 - 2026)

Veracyte has disclosed Net Income towards Common Stockholders across 15 years of filings, most recently posting $28.7 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $28.7 million, up 306.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.0 million (up 166.3% YoY), and the FY2025 annual result was $66.4 million, up 174.89% from the prior year.
• Net Income towards Common Stockholders came in at $28.7 million for Q1 2026 at Veracyte, down from $41.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $41.1 million in Q4 2025 to a low of -$29.6 million in Q3 2023.
• The 5-year median for Net Income towards Common Stockholders is -$1.9 million (2024), against an average of $488235.3.
• Across the five-year window, Net Income towards Common Stockholders sank 640.92% in 2023 and jumped 704.77% in 2025, its largest moves.
• Veracyte's Net Income towards Common Stockholders stood at -$3.8 million in 2022, then tumbled by 640.92% to -$28.3 million in 2023, then soared by 118.08% to $5.1 million in 2024, then surged by 704.77% to $41.1 million in 2025, then sank by 30.31% to $28.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $28.7 million (Q1 2026), $41.1 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.